S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains

Physiomics (PYC) Competitors

GBX 1.15
-0.05 (-4.17%)
(As of 03:17 AM ET)

PYC vs. NFX, EVG, APTA, OVB, OCTP, FAB, IXI, VAL, GENF, and ROQ

Should you be buying Physiomics stock or one of its competitors? The main competitors of Physiomics include Nuformix (NFX), Evgen Pharma (EVG), Aptamer Group (APTA), Ovoca Bio (OVB), Oxford Cannabinoid Technologies (OCTP), Fusion Antibodies (FAB), IXICO (IXI), ValiRx (VAL), Genflow Biosciences (GENF), and Roquefort Therapeutics (ROQ). These companies are all part of the "biotechnology" industry.

Physiomics vs.

Physiomics (LON:PYC) and Nuformix (LON:NFX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, community ranking, media sentiment, analyst recommendations, institutional ownership and risk.

Physiomics received 12 more outperform votes than Nuformix when rated by MarketBeat users. However, 66.67% of users gave Nuformix an outperform vote while only 55.56% of users gave Physiomics an outperform vote.

CompanyUnderperformOutperform
PhysiomicsOutperform Votes
80
55.56%
Underperform Votes
64
44.44%
NuformixOutperform Votes
68
66.67%
Underperform Votes
34
33.33%

In the previous week, Physiomics' average media sentiment score of 0.00 equaled Nuformix'saverage media sentiment score.

Company Overall Sentiment
Physiomics Neutral
Nuformix Neutral

Physiomics has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500. Comparatively, Nuformix has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Physiomics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Nuformix
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Nuformix has a net margin of 0.00% compared to Physiomics' net margin of -70.32%. Nuformix's return on equity of -27.25% beat Physiomics' return on equity.

Company Net Margins Return on Equity Return on Assets
Physiomics-70.32% -62.94% -37.22%
Nuformix N/A -27.25%-17.20%

Physiomics has higher revenue and earnings than Nuformix.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Physiomics£900.71K1.73N/AN/AN/A
Nuformix£50K31.13-£1.20MN/AN/A

0.1% of Physiomics shares are held by institutional investors. Comparatively, 0.2% of Nuformix shares are held by institutional investors. 6.3% of Physiomics shares are held by insiders. Comparatively, 15.0% of Nuformix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Nuformix beats Physiomics on 8 of the 11 factors compared between the two stocks.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PYC vs. The Competition

MetricPhysiomicsBiotechnology IndustryMedical SectorLON Exchange
Market Cap£1.56M£394.57M£4.75B£1.36B
Dividend Yield6.20%3.48%2.90%11.99%
P/E Ratio-13.83221.95270.611,715.80
Price / Sales1.7310,489.462,413.97324,116.42
Price / Cash4.2111.7347.5432.83
Price / BookN/A5.194.632.51
Net IncomeN/A-£51.25M£102.17M£179.61M
7 Day Performance4.55%-3.68%-4.80%-0.38%
1 Month Performance-14.81%-4.33%-4.36%7.48%
1 Year Performance-58.93%52.25%10.22%16.17%

Physiomics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NFX
Nuformix
0 of 5 stars
GBX 0.23
+12.2%
N/A-14.9%£1.88M£50,000.00-1.633Gap Up
EVG
Evgen Pharma
0 of 5 stars
GBX 0.80
+6.7%
N/A-80.6%£2.20MN/A-80.0010
APTA
Aptamer Group
0 of 5 stars
GBX 0.58
-2.8%
N/A-98.2%£2.73M£1.75M-7.2946
OVB
Ovoca Bio
0 of 5 stars
GBX 0.66
+19.1%
N/A-88.6%£534,000.00N/A-32.755
OCTP
Oxford Cannabinoid Technologies
0 of 5 stars
GBX 0.35
+1.5%
N/A-69.0%£3.76MN/A-53.107
FAB
Fusion Antibodies
0 of 5 stars
GBX 4.10
+5.2%
N/A-89.1%£3.91M£1.58M-45.6048High Trading Volume
IXI
IXICO
0 of 5 stars
GBX 8.52
-2.7%
N/A-58.5%£4.12M£6.67M-425.7589
VAL
ValiRx
0 of 5 stars
GBX 3.63
+0.8%
N/A-65.9%£4.80MN/A-121.008
GENF
Genflow Biosciences
0 of 5 stars
GBX 1.80
+5.9%
N/A-54.7%£5.27MN/A-256.005
ROQ
Roquefort Therapeutics
0 of 5 stars
GBX 4.40
flat
N/A-35.0%£5.68M£637.00-381.259

Related Companies and Tools

This page (LON:PYC) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners